Back
Luna Innovations 10K Form
Buy
55
LUNA
Luna Innovations
Last Price:
$2.15
Seasonality Move:
-1.84%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-14 | 10Q | LUNA/Luna Innovations Quarterly |
2023-08-10 | 10Q | LUNA/Luna Innovations Quarterly |
2023-05-09 | 10Q | LUNA/Luna Innovations Quarterly |
2022-11-10 | 10Q | LUNA/Luna Innovations Quarterly |
2022-08-12 | 10Q | LUNA/Luna Innovations Quarterly |
2022-05-16 | 10Q | LUNA/Luna Innovations Quarterly |
Receive LUNA News And Ratings
See the #1 stock for the next 7 days that we like better than LUNA
LUNA Financial Statistics
Sales & Book Value
Annual Sales: | $109.5M |
---|---|
Cash Flow: | $0 |
Price / Cash Flow: | 0 |
Annual Sales: | $0.00 |
Price / Book: | 0.74 |
Profitability
Net Income (TTM): | $0 |
---|---|
Gross Margin: | $66.5M |
Return on Equity: | 0% |
Return on Assets: | 0% |
Luna Innovations Earnings Forecast
Key Luna Innovations Financial Ratios
-
The Gross Profit Margin over the past 22 years for LUNA is 60.73%.
-
The Selling, General & Administrative Expenses for LUNA have been equal to 52.55% of Gross Profit Margin.
-
The Research & Development expenses have been 9.90% of Revenue.
-
The Interest Expense is 9.24% of Operating Income.
-
The Net Earning history of LUNA is 8.47% of Total Revenues.
-
Per Share Earnings over the last 22 years have been positive in 10 years.
Luna Innovations Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Electronic Equipment, Instruments & Components |
Sector: | Information Technology |
Current Symbol: | LUNA |
CUSIP: | 550351 |
Website: | lunainc.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 7.32 |
---|---|
Forward P/E Ratio: | 4.66 |
LUNA Technical Analysis vs Fundamental Analysis
Buy
55
Luna Innovations (LUNA)
is a Buy
Is Luna Innovations a Buy or a Sell?
-
Luna Innovations stock is rated a BuyThe current Luna Innovations [LUNA] share price is $2.05. The Score for LUNA is 55, which is 10% above its historic median score of 50, and infers lower risk than normal.